{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-045804","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.940540+00:00","generated_at":"2026-05-30T00:29:10.606321+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Celcuity Q3 net loss $29.8M ($0.70/sh); VIKTORIA-1 wild-type cohort 100% enrolled","bullets":["PIK3CA wild-type cohort of VIKTORIA-1 100% enrolled; topline data expected late Q1 2025 or Q2 2025.","Celcuity reports Q3 2024 net loss $29.8M ($0.70/sh) vs $18.4M ($0.83/sh) in Q3 2023.","R&D expenses $27.6M, up from $17.5M; total operating expenses $30.1M.","Cash, cash equivalents and investments ~$264M at end of Q3 2024, expected to fund through 2026.","VIKTORIA-2 Phase 3 first patient enrollment expected Q2 2025; Phase 1b/2 mCRPC data expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-045804","json":"https://secwatch.observer/filing/0001493152-24-045804.json","markdown":"https://secwatch.observer/filing/0001493152-24-045804.md","text":"https://secwatch.observer/filing/0001493152-24-045804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315224045804/0001493152-24-045804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315224045804/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:29:10.606321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}